Persistence on warfarin in patients with atrial fibrillation: Experience in australia 2006-2009

Australian Family Physician

Volumn 42, Issue 8, 2013, Pages 659-661

  Simons, Leon A ^a   Ortiz, Michael ^a   Germanos, Peter ^b   Calcino, Gordon ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Boehringer Ingelheim Pty Ltd   (Australia)

^c HI Connections Pty Ltd   (Australia)

Author keywords

Atrial fibrillation; Medication persistence; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ARTICLE; AUSTRALIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LONGITUDINAL STUDY; MALE; MEDICATION COMPLIANCE; STATISTICS;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; AUSTRALIA; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; WARFARIN;

EID: 84884163344     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
2. Gattellari M, Goumas C, Aitken R, Worthington JM. Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM Study (a program of research informing stroke management). Cerebrovasc Dis 2011;32:370-82.
3. NPS MedicineWise. Good anticoagulant practice. National Prescribing Service; February 2013. Available at: www.nps.org.au/ [Accessed on 4 February 2013]
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
5. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49.
6. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulantas for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;4:51-60.
7. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Juurlink DN. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9.
8. Song X, Sander SD, Varker H, Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 2012;12:245-53.
9. Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011;77:1182-90.
10. Senes S, Penm E. Medicines for cardiovascular health: are they used appropriately? Cat No CVD Canberra: AIHW 2007.
11. Gattellari M, Worthington JM, Zwar NA, Middleton S. The management of nonvalvular atrial fibrillation in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey. BMC Fam Pract 2008;9:62.
12. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation. A representative survey of Australian family physicians. Stroke 2008;39:227-30.
13. Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy. Experience in Australia 2006-2010. Aust Fam Physician 2011;40:319-22.
14. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience 2004-2006. Med J Aust 2008;188:224-27.
15. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.